How PharmEasy Survived a 90% Valuation Cut and a Broken Loan Covenant: A Case Study
Anubha A Pathak
9 November 202620 min read

PharmEasy started in 2015 as an online pharmacy. Then it went shopping. It merged with a medicine distributor, bought its rival Medlife with shares, and took control of the listed lab chain Thyrocare, partly with borrowed money. By October 2021, investors valued it at $5.6B, and an IPO was meant to pay down the debt.
The IPO never happened. PharmEasy refinanced with Goldman Sachs at a reported 17–18%, then broke a covenant, a promise in the loan terms, to raise new equity. No payment was missed. In 2023, it sold new shares through a rights issue, which offers them to existing shareholders first, at about a tenth of the peak price. Then it shrank to fix its margins, swapped in cheaper debt and sold Thyrocare shares down to 51%. In August 2026, it said it was debt-free.
So how does a company lose about 90% of its value and keep going? Here are the 13 calls that decided it.
Company snapshot#
Company
PharmEasy (parent: API Holdings)
Founded
2015 (PharmEasy); parent API Holdings incorporated in 2019
Sector
Healthtech: online pharmacy, B2B pharma distribution and diagnostics
Product type
Consumer pharmacy app, plus a B2B distribution platform (Retailio)
Capital raised
About $1.07B raised in the 2019–2021 rounds (a sum of reported rounds), plus 2022 insider notes and a 2023–24 rights issue of up to ₹3,500 crore (no confirmed total)
Key investors
Temasek, Prosus, TPG Growth, Janus Henderson, Neuberger Berman, Bessemer, Eight Roads, Fundamentum, Ranjan Pai's MEMG, 360 ONE
Operating status
Running. Unlisted; says it has been debt-free since August 2026. Owns 51.02% of listed Thyrocare
GC series role
Operating Finance
| Attribute | Detail |
|---|---|
| Company | PharmEasy (parent: API Holdings) |
| Founded | 2015 (PharmEasy); parent API Holdings incorporated in 2019 |
| Sector | Healthtech: online pharmacy, B2B pharma distribution and diagnostics |
| Product type | Consumer pharmacy app, plus a B2B distribution platform (Retailio) |
| Capital raised | About $1.07B raised in the 2019–2021 rounds (a sum of reported rounds), plus 2022 insider notes and a 2023–24 rights issue of up to ₹3,500 crore (no confirmed total) |
| Key investors | Temasek, Prosus, TPG Growth, Janus Henderson, Neuberger Berman, Bessemer, Eight Roads, Fundamentum, Ranjan Pai's MEMG, 360 ONE |
| Operating status | Running. Unlisted; says it has been debt-free since August 2026. Owns 51.02% of listed Thyrocare |
| GC series role | Operating Finance |
Timeline#
2015
Dharmil Sheth and Dhaval Shah launch PharmEasy, an online pharmacy. Siddharth Shah's team runs Ascent Health, a pharma distributor.
Aug 2020
PharmEasy, Ascent Health and four other companies merge into one holding company, API Holdings.
Dec 2020
Agrees to buy rival Medlife for ₹1,082.76 crore, paid entirely in new shares.
Jun 2021
Agrees to buy 66.14% of listed lab chain Thyrocare for ₹4,546.49 crore, partly with borrowed money.
Oct 2021
Raises about $350M at a $5.6B valuation ahead of a planned IPO.
Nov 2021
Files for a ₹6,250 crore IPO, with ₹1,929 crore set aside to repay debt.
2022
Borrows about ₹2,280 crore from Goldman Sachs for five years, at a reported 17–18%, to refinance the Thyrocare debt.
Aug 2022
Withdraws the IPO papers, citing market conditions.
Jun 2023
Has not raised the new equity the Goldman loan required, and breaches a covenant. No missed payment is reported.
Oct 2023
A ₹3,500 crore rights issue, priced at about a 90% valuation cut, closes. The company says demand beat the issue size.
Apr 2024
₹1,804 crore of new shares are allotted, led by Ranjan Pai's family office, at an estimated $710M valuation.
Jan 2025
Three co-founders step back. The company says its operations now bring in as much cash as they use.
Sep 2025
₹1,700 crore of new bonds replace the Goldman-era debt.
Aug 2026
Sells more Thyrocare shares and keeps 51.02%. The company says it has repaid ₹1,050 crore and is debt-free.
Oct 2026
FY26 accounts reportedly show a ₹520 crore loss on ₹6,618.5 crore of revenue, a loss 67% smaller than the year before.
| Date | Event |
|---|---|
| 2015 | Dharmil Sheth and Dhaval Shah launch PharmEasy, an online pharmacy. Siddharth Shah's team runs Ascent Health, a pharma distributor. |
| Aug 2020 | PharmEasy, Ascent Health and four other companies merge into one holding company, API Holdings. |
| Dec 2020 | Agrees to buy rival Medlife for ₹1,082.76 crore, paid entirely in new shares. |
| Jun 2021 | Agrees to buy 66.14% of listed lab chain Thyrocare for ₹4,546.49 crore, partly with borrowed money. |
| Oct 2021 | Raises about $350M at a $5.6B valuation ahead of a planned IPO. |
| Nov 2021 | Files for a ₹6,250 crore IPO, with ₹1,929 crore set aside to repay debt. |
| 2022 | Borrows about ₹2,280 crore from Goldman Sachs for five years, at a reported 17–18%, to refinance the Thyrocare debt. |
| Aug 2022 | Withdraws the IPO papers, citing market conditions. |
| Jun 2023 | Has not raised the new equity the Goldman loan required, and breaches a covenant. No missed payment is reported. |
| Oct 2023 | A ₹3,500 crore rights issue, priced at about a 90% valuation cut, closes. The company says demand beat the issue size. |
| Apr 2024 | ₹1,804 crore of new shares are allotted, led by Ranjan Pai's family office, at an estimated $710M valuation. |
| Jan 2025 | Three co-founders step back. The company says its operations now bring in as much cash as they use. |
| Sep 2025 | ₹1,700 crore of new bonds replace the Goldman-era debt. |
| Aug 2026 | Sells more Thyrocare shares and keeps 51.02%. The company says it has repaid ₹1,050 crore and is debt-free. |
| Oct 2026 | FY26 accounts reportedly show a ₹520 crore loss on ₹6,618.5 crore of revenue, a loss 67% smaller than the year before. |
The 13 decisions#
Watch for one pattern as you read: the early deals were paid for with shares and debt, and most of the later calls were about who would pay that debt back.
Decision 1: Should the app and the distributor become one company? (2020) #
PharmEasy began in 2015 as an online pharmacy, started by Dharmil Sheth and Dhaval Shah. Alongside it sat Ascent Health, a pharma distribution business run by Siddharth Shah, Hardik Dedhia and Harsh Parekh. The two were already tied together: Ascent was PharmEasy's investor entity.
They could keep two separate companies, linked by a supply contract. Or they could put both under one holding company, so the consumer app and the bulk distribution business sat in one set of books. There was a smaller question inside the big one: run the PharmEasy marketplace inside the group, or license it to an outside operator.
They merged. API Holdings was incorporated in March 2019. In June 2020, the company tribunal in Mumbai (NCLT) approved one scheme that folded PharmEasy's company, Ascent Health and four others into it, effective August 2020. The PharmEasy marketplace itself was licensed to a third-party operator.
Selling to businesses became most of the revenue. In FY26, the B2B side reportedly brought in ₹4,082.4 crore, against ₹1,334.5 crore from consumers.
Decision 2: Pay for a rival in cash, or in shares? (2020) #
Medlife was a direct rival, founded in 2014, with about $56.5M raised. PharmEasy had last been valued at about $700M in November 2019, when Temasek led a $220M round. The two filed for merger approval with the Competition Commission of India (CCI) in August 2020, and it was cleared on 22 September.
API could pay cash, which keeps the owners' stakes whole but drains the bank account. It could pay in new shares, which saves the cash but hands part of the company to the sellers. Or it could skip the deal and keep fighting Medlife for the same customers.
It paid in shares. Under a December 2020 agreement, API bought Medlife for ₹1,082.76 crore, paid entirely in new preference shares (CCPS, a kind of share that turns into ordinary shares later). Medlife's holders ended up with 19.95% of the combined company.
No cash left the company, but the existing owners gave up about a fifth of it. Medlife's pending court cases, three petitions from chemist associations challenging online medicine sales, came along and became API's own. They sat among the 117 legal matters the group listed in its 2021 IPO papers, worth ₹157.01 crore in all, of which ₹123.47 crore was claimed against the group. Four months after the deal, the combined company raised a $350M Series E led by Prosus and TPG Growth, at a valuation estimated at $1.5B.

Decision 3: Buy a listed lab chain, partly with borrowed money? (2021) {#decision-3}#
Fresh from the Series E, Siddharth Shah met Thyrocare founder Dr A. Velumani on 25 May 2021. They signed a confidentiality agreement on 10 June and committed to close by 30 June. Thyrocare was a profitable diagnostics chain, listed on the stock market.
API could buy control, take a minority stake or a lab partnership, or build its own diagnostics business from scratch. And if it bought control, it had to decide how to pay: with equity alone, or with equity plus a loan taken for the deal.
It bought control and used both. Subsidiary Docon bought 66.14% for ₹4,546.49 crore, at ₹1,300 a share. An open offer, where the buyer of a big stake in a listed company offers to buy more shares from the public at the same price, added 5.07% for ₹348.80 crore. About $300M reportedly came from existing investors, and Velumani reinvested in API for under 5%. The loan reportedly came from Kotak Mahindra Bank, and by 15 September 2021 the group's secured term loans stood at ₹2,009.91 crore.
Thyrocare became the group's profit engine. In FY25, it made ₹90.8 crore of profit on ₹687.4 crore of revenue. It also became the group's main collateral. Docon's whole 71.06% stake was later pledged to lenders, which means the lenders could take the shares if the loans were not repaid.
Decision 4: Raise at the peak, and let early backers cash out? (2021) #
By October 2021, the IPO was weeks away. New investors such as Janus Henderson, Neuberger Berman, ADQ and Steadview wanted in before the listing. API could raise a pre-IPO round that mixed new money with share sales by early investors. It could take only new money, so every rupee landed in the company. Or it could skip the round and go straight to the IPO.
It mixed the two. The round raised about $350M at a $5.6B valuation. Of that, $204M was primary money, which goes into the company, and about $150M was secondary, where early investors sell their shares and the money goes to them. Fundamentum, Eight Roads and Bessemer partly exited, and the five founders bought about $40M of the shares on sale.
That price became the benchmark for everything after it. The same new investors later marked their stakes down, cutting the value they put on PharmEasy in their own books. Neuberger Berman put it at $4.4B in February 2023. Janus Henderson marked it at about $2.8B, then at about $458M by June 2024, 92% below the peak.
Decision 5: Can an IPO pay down the debt? (2021) #
API was growing fast and losing money fast. FY21 revenue was ₹2,335.27 crore, with a loss of ₹641.34 crore, and the first quarter of FY22 alone lost ₹313.89 crore. Borrowings stood at ₹2,494.73 crore, at interest rates from 7.80% to 15.5% a year. It could file for an IPO in early 2022. It could stay private and raise another private round. Or it could sell part of Thyrocare to cut the debt.
It filed. In November 2021, API filed its draft IPO papers, the DRHP, for a ₹6,250 crore IPO made up entirely of new shares. ₹1,929 crore was set aside to repay borrowings by FY23, ₹1,259 crore for organic growth and ₹1,500 crore for acquisitions. SEBI, the market regulator, issued its observations in February 2022, a step that lets a company go ahead.
Chemist and trader bodies asked SEBI to reject the IPO. Then listed tech stocks fell hard. By August 2022, Paytm was about 60% below its high and Zomato about 63%. The IPO never launched.
Decision 6: List at a lower price, or pull the IPO? (2022) #
In July 2022, PharmEasy was reportedly in talks to raise $200M at $3.8B, about 30% below its last round. A pre-IPO down round, meaning a raise at a lower price than before, sought $250M–$300M and reportedly failed.
It could go ahead and list at a lower valuation. It could keep trying for a private down round with new investors. Or it could withdraw the IPO and raise from the shareholders it already had. In August 2022, API withdrew its IPO papers, citing market conditions. It planned a rights issue of preference shares at about ₹100 each. In a rights issue, existing shareholders get the right to buy new shares in proportion to what they already own.
In October 2022, insiders were offered up to ₹750 crore of convertible notes, loans that can later turn into shares, and about ₹650 crore reportedly came in. Temasek-backed EvolutionX lent an undisclosed amount. The ₹1,929 crore debt paydown that the IPO was meant to fund never happened.

Decision 7: Borrow from Goldman Sachs at 17–18%? (2022) #
The bank loan used to buy Thyrocare needed refinancing, which means replacing it with a new loan. And the IPO money was not coming. API could refinance with expensive private credit, borrowing from an investment firm rather than a bank. It could raise equity at a lower valuation, which it tried, but no round closed. Or it could sell part of Thyrocare.
It went to Goldman Sachs, which lent about ₹2,280 crore ($285M) for five years at a reported 17–18% a year. The security was all of API's assets plus the Thyrocare shares. The loan also carried a covenant, a promise written into the loan terms, that API would raise about ₹1,000 crore ($120M) of new equity. Reports differ on the exact date and amount of the loan.
By June 2023, the new equity had not been raised, and the covenant was breached. That is not the same as missing a payment, and no missed payment was reported. About $50M of the loan had already been repaid. The interest bill stayed heavy: finance costs for FY24 were reportedly ₹727.9 crore.
Decision 8: How hard do you cut when the money stops? (2022) #
FY22 revenue was ₹5,728.8 crore and the loss was ₹2,731.7 crore. The FY23 accounts later restated that loss at ₹3,992.4 crore. Funding talks were stalling.API could cut deep. It could keep spending to hold its share against Tata 1mg and Netmeds. Or it could leave consumer delivery altogether.
It cut. About 40 people were let go at Docon in June 2022, and more across teams in November and December, reportedly hundreds. The company set a target to be profitable by April 2023. Marketing spend fell from ₹494 crore in FY22 to ₹235 crore in FY23, and employee costs fell 12%.
The headline FY23 loss was ₹5,211.7 crore, but ₹2,921.9 crore of that was a write-down in the value of assets on the books. Before the write-down, the loss fell to ₹2,289.8 crore, from ₹2,731.7 crore. Co-founder Dhaval Shah said the company made ₹60 crore of EBITDA (profit before interest, tax, depreciation and amortisation) from April to September 2023, a company claim. By October 2023, Inc42 counted nearly 500 layoffs since 2022.
Decision 9: How do you fix a broken covenant? (2023) #
After the breach, the board and shareholders reportedly wanted Goldman repaid. At a meeting of all investors on 17 July 2023, they agreed on a rights issue.API could restructure the loan and turn part of it into shares, and Goldman did weigh converting about $38M–$40M. It could sell Thyrocare, or control of it, the asset Inc42 noted the lender could potentially take. Or it could ask shareholders for new equity at a steep discount.
It went to the shareholders. The rights issue grew from ₹2,400 crore to ₹3,500 crore and was priced at about ₹5 a share, against ₹50 at the peak round. That valued the company at a reported $500M–$600M, about a 90% cut. PharmEasy planned to pay Goldman $100M–$150M from the money.
The issue closed in October 2023, and Dhaval Shah said demand was higher than the shares on offer. Goldman, Prosus and Temasek took part. The rest of the Goldman-era debt was refinanced two years later, in September 2025.

Decision 10: Who gets first claim on cheap shares? (2023) #
Manipal Group chairman Ranjan Pai's family office offered to put in up to ₹1,300 crore. Some investors objected to selling him shares at such a low price.API could let Pai take a large block up front. It could give existing holders the first right to their share, with Pai as a backstop, an investor who buys whatever the others do not take. Or it could raise from insiders only, with no backstop at all.
The board gave existing shareholders the first right, and approved Pai's binding offer only for the part they left unsubscribed. After the CCI approved it in March 2024, ₹1,804 crore ($216M) of preference shares were allotted. Pai's family office, MEMG, reportedly led with ₹800 crore, alongside Prosus with ₹221 crore, 360 ONE with ₹200 crore and Temasek with ₹183 crore. The post-money valuation, the company's value including the new money, was estimated at $710M. Pai reportedly holds more than 12% of the company.
Decision 11: Shrink revenue to fix margins? (2024) #
FY24 revenue fell 14.8% to ₹5,664 crore, with a loss of ₹2,533.5 crore. The leadership changed too. Co-founders Dharmil Sheth, Dhaval Shah and Hardik Dedhia stepped back in January 2025, and in August 2025 Thyrocare's Rahul Guha became CEO of the group.
API could chase sales to rebuild its IPO story. It could drop low-margin customers and push diagnostics and private-label products sold under its own brand. Or it could leave consumer sales entirely.
It chose margins. Its FY25 board report says the group put higher-margin customers first, dropped low-margin business, focused on diagnostics and private label, and cut staff.
In January 2025, the company said it had reached operating cash-flow break-even, meaning its day-to-day business brought in as much cash as it used. FY25 revenue rose 3.7% to ₹5,872 crore, and the loss fell to about ₹1,517–1,572 crore (reports differ). FY26 revenue reportedly rose 12.7% to ₹6,618.5 crore, with a loss of ₹520 crore.
Decision 12: Refinance with cheaper bonds and a smaller pledge? (2025) #
By 2025, the group's older debentures had a redemption value of ₹1,820 crore, with ₹1,545.4 crore still outstanding. Debentures are bonds: money borrowed from investors that has to be paid back, or redeemed, by a set date. These were secured on Docon's entire 71.06% stake in Thyrocare, and the Goldman loan was reportedly due by June 2026.
API could refinance. It could sell Thyrocare shares to repay. Or it could raise equity at a valuation below $1B.It refinanced. In September 2025, it raised ₹1,700 crore of non-convertible debentures (NCDs), bonds that cannot turn into shares. 360 ONE put in ₹1,231 crore, Micro Labs ₹210 crore, MVS Ventures ₹78 crore and Bennett Coleman ₹50 crore, with others making up the rest. The pledge on Thyrocare fell to 60.99% of the company. The interest rates on the new bonds were reportedly 11.1% and 14.5%.
The earlier debenture liability was cleared in full. And with cheaper debt in place, API had time to sell Thyrocare shares at market prices.
Decision 13: Sell down Thyrocare, but keep control? (2025) #
Thyrocare was growing fast. Its profit for the second quarter of FY26 rose 81% to ₹47.9 crore. It was also the collateral behind the group's debt. API could hold the full stake and keep carrying the debt. It could sell slices in the open market while keeping control. Or it could give up control, or merge Thyrocare into API.
It sold slices. On 24 October 2025, Docon sold 10.06% to mutual funds for ₹667.7 crore, at ₹1,252 a share, taking its stake from 71% to 61%. In August 2026, it sold another 9.90% and kept 51.02%.
API repaid ₹1,050 crore of term debt, redeemed the debentures on 14 August 2026 and had the pledge released. The company says it is now debt-free. Group CFO Alok Kumar Jagnani said this was done without going below 51% of Thyrocare.

FAQs#
Why did PharmEasy's valuation fall?
It peaked at $5.6B in a pre-IPO round in October 2021. The IPO was withdrawn in August 2022 after listed tech stocks fell, and in 2023, PharmEasy raised money from its shareholders at about a 90% valuation cut. One investor's filing put it at about $458M in June 2024.
Why did PharmEasy withdraw its IPO?
API Holdings withdrew its draft IPO papers in August 2022, citing market conditions. Listed tech stocks had fallen sharply, with Paytm about 60% and Zomato about 63% below their highs.
What happened with PharmEasy's Goldman Sachs loan?
In 2022 Goldman Sachs lent about ₹2,280 crore at a reported 17–18%, on the condition that PharmEasy raise about ₹1,000 crore of new equity. That condition was breached in June 2023, but no missed payment was reported. PharmEasy then ran a rights issue, and the rest of the Goldman-era debt was refinanced in September 2025.
Who invested in PharmEasy?
Temasek led a $220M round in 2019, and Prosus and TPG Growth led a $350M Series E in 2021. Janus Henderson and Neuberger Berman came in before the planned IPO. In 2024, Ranjan Pai's family office, MEMG, led a ₹1,804 crore allotment with Prosus, 360 ONE and Temasek.
Does PharmEasy still own Thyrocare?
Yes. Its subsidiary Docon sold down from about 71% in two steps, in October 2025 and August 2026, and kept 51.02%, which keeps control.
Is PharmEasy debt-free and profitable?
Its parent, API Holdings, says it has been debt-free since August 2026, after repaying ₹1,050 crore of term debt. It is not yet profitable for a full year: FY26 accounts reportedly show a ₹520 crore loss on ₹6,618.5 crore of revenue.
Sources#
- 1.API Holdings DRHP, Part 1, November 2021: merger, Medlife deal, Thyrocare purchase, IPO plan, FY21 and Q1 FY22 results, legal matters
- 1.API Holdings DRHP, Part 2, November 2021: borrowings and interest rates
- 1.Entrepreneur, February 2023: founders, PharmEasy launch, Ascent Health
- 1.Inc42, November 2021: founders and Ascent Health
- 1.DealStreetAsia, November 2019: Temasek's $220M round, $700M valuation
- 1.Inc42, September 2020: Medlife merger approval
- 1.Entrackr, April 2021: $350M Series E, valuation about $1.5B, Medlife holders' stake
- 1.YourStory, July 2021: Thyrocare deal timeline, Velumani's reinvestment
- 1.Business Today, June 2021: $300M raised for the Thyrocare deal
- 1.Inc42, October 2021: pre-IPO round at $5.6B
- 1.Entrepreneur, October 2021: pre-IPO round, secondary sales, founders' purchase
- 1.Inc42, December 2021: traders' body asks SEBI to reject the IPO
- 1.Business Today, February 2022: SEBI observations on the DRHP
- 1.Inc42, August 2022: IPO withdrawal, $3.8B talks, tech-stock falls
- 1.YourStory, August 2022: IPO withdrawal, rights issue plan
- 1.Outlook Startup, October 2022: ₹750 crore convertible notes
- 1.Inc42, November 2022: EvolutionX debt
- 1.Inc42, December 2022: layoffs, failed down round
- 1.People Matters, May 2023: layoffs, profitability target
- 1.Business Today, May 2023: investor markdowns
- 1.Inc42, June 2023: Goldman loan, covenant breach, Kotak debt
- 1.YourStory, June 2023: covenant breach, no missed payment, $50M repaid
- 1.Business Standard, July 2023: ₹2,400 crore rights issue, shareholders wanted Goldman repaid
- 1.Inc42, July 2023: all-investor meeting, Ranjan Pai's offer
- 1.Inc42, August 2023: ₹3,500 crore issue at about ₹5 a share, Goldman conversion talks
- 1.Inc42, October 2023: rights issue closes, EBITDA claim, layoff count
- 1.Inc42, January 2024: FY23 results and marketing spend
- 1.Inc42, March 2024: CCI approval for MEMG and 360 ONE
- 1.Entrackr, April 2024: ₹1,804 crore allotment at about $710M
- 1.TechCrunch, September 2024: about $458M, 92% below the peak
- 1.Entrackr, November 2024: FY24 results and finance costs
- 1.Entrackr, January 2025: co-founders step back, cash-flow break-even
- 1.Entrackr, August 2025: Rahul Guha becomes CEO
- 1.Inc42, September 2025: FY25 results
- 1.Entrackr, September 2025: FY25 results, Thyrocare's FY25 profit
- 1.Inc42, September 2025: B2B share of revenue, Ranjan Pai's stake
- 1.Entrackr, September 2025: ₹1,700 crore refinancing of the Goldman-era debt
- 1.Outlook Business, September 2025: NCD investors, pledge cut to 60.99%
- 1.Venture Intelligence, citing IFR, September 2025: interest rates on the new bonds
- 1.Entrackr, October 2025: 10.06% Thyrocare sale for ₹667.7 crore
- 1.Digital Health News, October 2025: Thyrocare sale to mutual funds
- 1.Inc42, August 2026: 51.02% stake kept, debt-free claim
- 1.Entrepreneur, August 2026: ₹1,050 crore repaid, CFO's statement
- 1.Inc42, October 2026: FY26 results, B2B and B2C revenue
Open gaps#
Peak valuation
Conflict
$5.6B, $5.4B or $5.1B–$5.6B across reports
Settled by
Company filings (MCA)
Status
Open
Goldman Sachs loan
Conflict
May or August 2022; about ₹2,280 crore, ₹2,700 crore or $300M; loan or bonds
Settled by
Charge and pledge filings
Status
Open
FY22 loss
Conflict
₹2,731.7 crore, ₹3,992.4 crore or ₹4,043 crore
Settled by
FY22 and FY23 annual filings
Status
Open
FY24 and FY25 losses
Conflict
FY24 ₹2,522–2,533.5 crore; FY25 ₹1,516.8 or ₹1,572.3 crore
Settled by
Annual reports
Status
Open
2023 rights issue
Conflict
Valuation of $500M–$600M or $710M; whether the 2024 allotment is part of the ₹3,500 crore
Settled by
Allotment filings
Status
Open
FY26 results
Conflict
Revenue and loss rest on one report
Settled by
FY26 annual report
Status
Open
| Gap | Conflict | Settled by | Status |
|---|---|---|---|
| Peak valuation | $5.6B, $5.4B or $5.1B–$5.6B across reports | Company filings (MCA) | Open |
| Goldman Sachs loan | May or August 2022; about ₹2,280 crore, ₹2,700 crore or $300M; loan or bonds | Charge and pledge filings | Open |
| FY22 loss | ₹2,731.7 crore, ₹3,992.4 crore or ₹4,043 crore | FY22 and FY23 annual filings | Open |
| FY24 and FY25 losses | FY24 ₹2,522–2,533.5 crore; FY25 ₹1,516.8 or ₹1,572.3 crore | Annual reports | Open |
| 2023 rights issue | Valuation of $500M–$600M or $710M; whether the 2024 allotment is part of the ₹3,500 crore | Allotment filings | Open |
| FY26 results | Revenue and loss rest on one report | FY26 annual report | Open |
Could you have made the call? Play the PharmEasy series on Generally Critical. [Play on GC →]
Want a career making calls like these? [Apply to Founder's Find →]
Practise on Founder's Find
Reading about a method takes an afternoon. Using it calmly under pressure takes practice.